

# Neil M Walker

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2296961/publications.pdf>

Version: 2024-02-01

16  
papers

1,342  
citations

759233

12  
h-index

940533

16  
g-index

18  
all docs

18  
docs citations

18  
times ranked

3223  
citing authors

#	ARTICLE	IF	CITATIONS
1	Fine mapping of type 1 diabetes susceptibility loci and evidence for colocalization of causal variants with lymphoid gene enhancers. <i>Nature Genetics</i> , 2015, 47, 381-386.	21.4	589
2	Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. <i>Nature Genetics</i> , 2009, 41, 1011-1015.	21.4	249
3	Statistical colocalization of genetic risk variants for related autoimmune diseases in the context of common controls. <i>Nature Genetics</i> , 2015, 47, 839-846.	21.4	128
4	Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial. <i>PLoS Medicine</i> , 2016, 13, e1002139.	8.4	117
5	Dissection of a Complex Disease Susceptibility Region Using a Bayesian Stochastic Search Approach to Fine Mapping. <i>PLoS Genetics</i> , 2015, 11, e1005272.	3.5	55
6	Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. <i>JCI Insight</i> , 2017, 2, .	5.0	46
7	Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial. <i>BMJ Open</i> , 2014, 4, e005559-e005559.	1.9	33
8	The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes. <i>JCI Insight</i> , 2018, 3, .	5.0	29
9	Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study. <i>BMJ Open</i> , 2015, 5, e009799.	1.9	20
10	Detection and correction of artefacts in estimation of rare copy number variants and analysis of rare deletions in type 1 diabetes. <i>Human Molecular Genetics</i> , 2015, 24, 1774-1790.	2.9	20
11	A Genome-Wide Assessment of the Role of Untagged Copy Number Variants in Type 1 Diabetes. <i>PLoS Genetics</i> , 2014, 10, e1004367.	3.5	17
12	Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial. <i>Wellcome Open Research</i> , 2017, 2, 28.	1.8	14
13	Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). <i>Trials</i> , 2015, 16, 86.	1.6	9
14	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. <i>IScience</i> , 2022, 25, 103971.	4.1	7
15	Returning findings within longitudinal cohort studies: the 1958 birth cohort as an exemplar. <i>Emerging Themes in Epidemiology</i> , 2014, 11, 10.	2.7	3
16	All or Nothing: The False Promise of Anonymity. <i>Data Science Journal</i> , 2017, 16, .	1.3	1